<DOC>
	<DOCNO>NCT00972686</DOCNO>
	<brief_summary>P3K112826 Phase I , first-time-in-human dose escalation study subject refractory malignancy . The primary objective study determine recommend Phase II dose GSK2126458 base safety tolerability , pharmacokinetics , pharmacodynamics preliminary evidence clinical activity . Secondary objective characterize pharmacokinetics GSK2126458 ; explore relationship GSK2126458 pharmacokinetics , pharmacodynamics , response prediction biomarkers clinical endpoint .</brief_summary>
	<brief_title>Dose-Escalation Study GSK2126458</brief_title>
	<detailed_description>This study Phase I , first-time-in-human dose escalation study subject refractory solid tumor lymphoma . The primary objective study determine recommend Phase II dose GSK2126458 base safety tolerability , pharmacokinetics , pharmacodynamics preliminary evidence clinical activity . Secondary objective characterize pharmacokinetics GSK2126458 ; explore relationship GSK2126458 pharmacokinetics , pharmacodynamics , response prediction biomarkers clinical endpoint . Subjects solid tumor lymphoma initially receive oral GSK2126458 daily 28 consecutive day 28 day cycle . Subjects may dose twice day may dose intermittent schedule depend safety , pharmacokinetic pharmacodynamic result become available study progress . The start dose 0.1 mg day . Expansion cohort conduct test tumor pharmacodynamics , explore toxicity profile look preliminary evidence activity subject tumor PIK3CA mutation . The recommended Phase II dose low dose explore ( MTD ) maintain biologic activity acceptable tolerability profile .</detailed_description>
	<criteria>Histologically cytologically confirm diagnosis solid tumor malignancy , lymphoma Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Female male willing take measure avoid pregnancy self partner , include abstinence , double barrier method . Adequate organ system function Use investigational anticancer medication within 28 day 5 halflives precede first dose GSK2126458 . Chemotherapy within last 3 week ( 6 week prior nitrosourea mitomycin C Any major surgery , radiotherapy , immunotherapy within last 4 week . Prior use PI3K inhibitor . Current use prohibit medication require medication treatment GSK2126458 . Presence active gastrointestinal disease condition know interfere significantly absorption , distribution , metabolism , excretion drug . Unresolved toxicity great Grade 1 previous anticancer therapy except alopecia . QTc interval ≥ 480 msec . History acute coronary syndrome ; Class II , III , IV heart failure ; stroke subarachnoid hemorrhage . Systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg . Previously diagnose Type 1 diabetes mellitus . Subjects Type 2 diabetes prohibit dose escalation part study . Symptomatic untreated leptomeningeal brain metastasis . Primary malignancy central nervous system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Phosphoinositide 3-kinase inhibitor</keyword>
</DOC>